Association of serum anti-neuraminidase antibody with resistance to influenza in man.
about
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesPolarizing T and B Cell Responses by APC-Targeted Subunit VaccinesPathogenicity and transmissibility of North American triple reassortant swine influenza A viruses in ferretsMolecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza virusesNonreplicating influenza A virus vaccines confer broad protection against lethal challengeThe shifting demographic landscape of influenzaAvirulent Avian influenza virus as a vaccine strain against a potential human pandemic.Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnelAdenoviral vectors as novel vaccines for influenza.Heterosubtypic immunity to influenza A virus: where do we stand?H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.A review of the changes to the licensing of influenza vaccines in Europe.Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicityInfluenza vaccines: from surveillance through production to protection.The shifting demographic landscape of pandemic influenza.Viral vector-based influenza vaccines.Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.Cross-protective immunity to influenza A viruses.Structural basis of influenza virus neutralization.Why do influenza virus subtypes die out? A hypothesis.Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.Targets for the induction of protective immunity against influenza a viruses.Live Victoria/75-ts-1[E] influenza A virus vaccines in adult volunteers: role of hemagglutinin immunity in protection against illness and infection caused by influenza A virus.The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferretsPassive immune neutralization strategies for prevention and control of influenza A infections.Temperature-sensitive mutants of influenza A virus: evaluation of A/Victoria/3/75-ts-1[E] recombinant viruses in volunteers.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine designProtection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trialAn influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?Mapping antibody epitopes of the avian H5N1 influenza virusA high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populationsSingle-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
P2860
Q24615003-4E527F30-F71E-4ECD-996E-5379777DB556Q26800145-58792963-ABF1-4466-B710-5296DDC55920Q28386553-BBA4D79C-CD1E-4E59-96A4-F95E5AB094E7Q28387782-0F62B0A1-8885-456C-B3E3-532D346CE76EQ28392109-839F08C4-22BC-46A8-9F9E-7C5214F32362Q28750491-3DA10F4A-3A86-42C0-A29C-1F357629645EQ30322954-DBF2AE90-62C6-4AE6-807C-B622A8420264Q30356053-4CB235E3-D01F-4E90-B3F7-BC318CF1BCECQ30370445-678F0406-66D7-4BB3-A8D1-62D5A8FBE716Q30370995-5BB8AE33-296D-42B1-8B59-1057DF6A361DQ30371297-F9A9E498-AC24-43B9-B1BA-7BCDC7127DFEQ30373917-6E87ACAB-6A6B-4A34-9860-72C4D1F56D5EQ30378263-6A232733-9A06-4D48-8916-624FFA085E1AQ30379967-DD79FB36-EDE3-4DB5-A11D-5FE4E0046338Q30380287-641D8BA9-7005-4206-9093-6113CA07E981Q30382650-79E2A2F2-735F-4B11-9114-C98E2F03D886Q30382921-C16378B4-1885-4300-B337-549F6744AD88Q30385118-D81909A2-CC9A-4CD5-A6E6-F25953C55BA2Q30386197-AD6FC1EC-C924-469A-96DB-CD7862A75764Q30390938-E21E7EE9-F800-40DB-A420-7A444B259679Q30395315-89519AF4-292E-484A-A470-8922DC040135Q30396399-8815F91B-A26F-49DE-9F4A-090C3F234819Q30398754-B0B0BB6A-3088-41E5-9F34-88BC583D937AQ30406519-CECCF8AE-9310-4857-AEE5-96D68C9398FAQ30407834-7C21FC66-B37E-465D-B215-B9742BAE2421Q30408100-AE8D2BA0-8F39-49CF-9DB0-E80BCFCB1FCBQ30409789-D7C0F10C-D70A-463B-8D32-093789EEEBCEQ30413023-05ADF666-4B81-4A26-A4DC-65131C6F72F0Q30413158-C94EB40B-9993-4EE5-A511-12DCC8DA94A9Q30413824-7190FA11-BB0F-4CC4-87B5-48A2B9DF6E77Q30416502-2F57F7EA-CA62-4CEF-8739-45A2E529BC44Q30418452-69796F8F-48B6-4628-AD56-6E9FBD4FBA0CQ30425783-799EE07D-111A-4715-ADAA-99036B7BC925Q30429009-3C03A4B2-F9D3-44B1-AC3F-41EDB77BDE7EQ30571702-48FCE27A-73DD-4899-AF34-9F400F575871Q33273605-B502EA3A-A0AD-4FA7-ADF3-6E9B35369884Q33432749-AA0040C8-97A0-4952-8B44-2EA3B566C88DQ33782762-FD181D99-3DF9-45C0-B212-B852BE27E713Q33907707-73B20732-DB2C-42CD-89AE-33A6384577FBQ34057785-BED12AF3-BB94-4A43-84B3-D784A43E272B
P2860
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
description
1972 nî lūn-bûn
@nan
1972年の論文
@ja
1972年学术文章
@wuu
1972年学术文章
@zh
1972年学术文章
@zh-cn
1972年学术文章
@zh-hans
1972年学术文章
@zh-my
1972年学术文章
@zh-sg
1972年學術文章
@yue
1972年學術文章
@zh-hant
name
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@en
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@nl
type
label
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@en
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@nl
prefLabel
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@en
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@nl
P2093
P1476
Association of serum anti-neuraminidase antibody with resistance to influenza in man.
@en
P2093
P304
P356
10.1056/NEJM197206222862502
P407
P577
1972-06-01T00:00:00Z